#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
β ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Hi everyone! Looking forward to tonight's #LCSMchat I am a medical oncologist @PennCancer @PennMedicine #LCSM @lcsmchat |
 | Danielle Pardue @Actorielle Good evening, friends! Excited to be together. Looked forward to this all day. π #lcsm |
 | Janet Freeman-Daily @JFreemanDaily Welcome to #LCSM Chat! Tonightβs chat will discuss βLiquid BxβIt pays to be vein.β (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g |
| Danielle Pardue @Actorielle RT @JFreemanDaily: Welcome to #LCSM Chat! Tonightβs chat will discuss βLiquid BxβIt pays to be vein.β (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g |
 | Upstage Lung Cancer @UpstageLungCanc RT @JFreemanDaily: Welcome to #LCSM Chat! Tonightβs chat will discuss βLiquid BxβIt pays to be vein.β (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g |
| Janet Freeman-Daily @JFreemanDaily Iβm your moderator Janet Freeman-Daily: writer (https://t.co/OBCc87ZwkG), science geek, stage IV #lungcancer patient and research advocate. I will be joined by TWO special guests! #lcsm |
 | Faces of Lung Cancer @LungCancerFaces Deana Hendrickson in sunny Los Angeles here. Iβll be tweeting from the @lcsmchat account tonight during #LCSM Chat. Weβre about to start. Join us! https://t.co/Tp4hiLHVe2 |
 | OncLive SOSS @OncLiveSOSS LISTEN: John V. Heymach, MD, PhD, of @MDAndersonNews, discusses the incidence of EGFR exon 20 insertions in lung cancer, and diagnostic challenges of identifying EGFR exon 20 insertions #lcsm https://t.co/5TkhcvqOd2 https://t.co/Fg3ac0pczt |
 | Jill Feldman @jillfeldman4 Hi All, looking forward to tonight's chat, although will be multitasking because @KUHoops is playing #RCJH #LCSM |
| Upstage Lung Cancer @UpstageLungCanc Happy Thursday, friends! Always an honor to be here. #lcsm |
 | GYN Cancer | #GYNCSM @gyncsm RT @AdvocateCollab: Advocates: Advocates: It's been a helluva year. What have we learned about Cancer & COVID19 in the past year? What do we still want/need to know? Registration to the #CCC19 retreat is open, please consider attending https://t.co/IUznen53es #OncoAlert #bcsm #btsm #gyncsm #lcsm #crcsm #mmsm |
 | Gia Sonata @RedGia RT @JFreemanDaily: Welcome to #LCSM Chat! Tonightβs chat will discuss βLiquid BxβIt pays to be vein.β (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g |
| Janet Freeman-Daily @JFreemanDaily RT @IASLC: Listen March 8 for a special edition of #LungCancerConsidered @StephenVLiu & co-host Paul Bunn are joined by, Dr. Tal Zaks, CMO at @moderna_tx & @acmoorephd. They discuss the development of the Moderna #COVID-19 vaccine. https://t.co/g50D8L1NAm #LCSM @HwakeleeMD @NarjustDumaMD https://t.co/eL0BfS797Z |
 | Erika Hlavacek @ErikaHlavacek Good Evening #lcsm chatters from Chicagoβ€οΈ |
 | Kristin Ito @KAdvocate_LCAM Warm hello from chilly Denver @lcsmchat Looking forward to tonight's discussion! #LCSM |
| Danielle Pardue @Actorielle RT @LungCancerFaces: Deana Hendrickson in sunny Los Angeles here. Iβll be tweeting from the @lcsmchat account tonight during #LCSM Chat. Weβre about to start. Join us! https://t.co/Tp4hiLHVe2 |
| Janet Freeman-Daily @JFreemanDaily Charu Aggarwal, MD, MPH, (@CharuAggarwalMD) is the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at Penn Medicine. https://t.co/tQ7zWYeGn2 #lcsm |
 | Lecia Sequist, MD, MPH @LeciaSequist @CharuAggarwalMD @PennCancer @PennMedicine @lcsmchat Hi everyone! So happy to be here tonight with my friend @CharuAggarwalMD I am medical oncologist @MGHCancerCenter @MGHThoracicOnc #LCSM |
 | #LCSM Chat @lcsmchat @Actorielle Hey lady! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Welcome to #LCSM Chat! Tonightβs chat will discuss βLiquid BxβIt pays to be vein.β (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g |
| Janet Freeman-Daily @JFreemanDaily Lecia Sequist, MD, MPH, (@LeciaSequist) is the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. https://t.co/fzqQxKbUwg #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Iβm your moderator Janet Freeman-Daily: Iβm your moderator Janet Freeman-Daily: writer (https://t.co/OBCc87ZwkG), science geek, stage IV #lungcancer patient and research advocate. I will be joined by TWO special guests! #lcsm |
 | Sara Whitlock @sjwhitlock Hello from Dayton, Ohio !#LCSM |
| Erika Hlavacek @ErikaHlavacek RT @LungCancerFaces: Deana Hendrickson in sunny Los Angeles here. Iβll be tweeting from the @lcsmchat account tonight during #LCSM Chat. Weβre about to start. Join us! https://t.co/Tp4hiLHVe2 |
| Janet Freeman-Daily @JFreemanDaily We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
 | kristen kimball @KimballKristen Kris (Kimball) from Boston here, excited about tonight's topic. Thank you! #LCSM |
| #LCSM Chat @lcsmchat @jillfeldman4 @KUHoops Hi Jill! #lcsm |
| #LCSM Chat @lcsmchat @UpstageLungCanc Welcome! #lcsm |
| Gia Sonata @RedGia Gia here from NC. Stage IV lung cancer since 9/2014. Looking forward to this discussion. #lcsm |
| #LCSM Chat @lcsmchat @ErikaHlavacek Hi Erika! #lcsm |
 | Triage Cancer @TriageCancer Excited to join tonight! We're a national nonprofit that provides free educational/informational resources about the legal and practical issues that can affect someone after a #cancer diagnosis. Always eager to learn from this group! #lcsm |
| #LCSM Chat @lcsmchat @KAdvocate_LCAM Hey Kristin! #lcsm |
| Janet Freeman-Daily @JFreemanDaily If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Charu Aggarwal, MD, MPH, (@CharuAggarwalMD) is the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at Penn Medicine. https://t.co/tQ7zWYeGn2 #lcsm |
 | B @B32598085 Hello from Ontario, Canada #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Lecia Sequist, MD, MPH, (@LeciaSequist) is the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. https://t.co/fzqQxKbUwg #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BSBreastCancer: Who's joining in for the #LCSM Chat tonight? All Cancers Chat #bcsm #btsm #ayacsm #gyncsm #orosm #Pcsm @LizSzabo |
| Danielle Pardue @Actorielle RT @LeciaSequist: @CharuAggarwalMD @PennCancer @PennMedicine @lcsmchat Hi everyone! So happy to be here tonight with my friend @CharuAggarwalMD I am medical oncologist @MGHCancerCenter @MGHThoracicOnc #LCSM |
 | Dave Bjork @bjork5 Hi friends, Dave Bjork here in Boston, host of the https://t.co/WePGnEdkmc #LCSM |
| #LCSM Chat @lcsmchat @sjwhitlock Hello Sara! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Hi everyone! Looking forward to tonight's #LCSMchat I am a medical oncologist @PennCancer @PennMedicine #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
 | Matthew Smeltzer @MattSmeltzer Hi Everyone! This is Matt, from Memphis. #LCSM |
| Danielle Pardue @Actorielle RT @JFreemanDaily: Lecia Sequist, MD, MPH, (@LeciaSequist) is the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. https://t.co/fzqQxKbUwg #lcsm |
| #LCSM Chat @lcsmchat @KimballKristen Hi Kris! #lcsm |
| #LCSM Chat @lcsmchat @RedGia Hey Gia! #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD #LCSM @lcsmchat |
| Dave Bjork @bjork5 She is awesome! #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @TriageCancer: Excited to join tonight! We're a national nonprofit that provides free educational/informational resources about the legal and practical issues that can affect someone after a #cancer diagnosis. Always eager to learn from this group! #lcsm |
| #LCSM Chat @lcsmchat @TriageCancer Welcome! #lcsm |
 | Eric Bernicker @EricBernicker Greetings from Houston where we have power, clean water and ...fewer masks π I am a thoracic medical oncologist. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @ChristianRolfo @JFreemanDaily @UMmedschool @isliquidbiopsy @LeciaSequist Good to see you Christian! #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb |
 | Deb Smith π»π§ @debsmithbeach Hi, Deb here from chilly, blustery NH. I had stable scans on 2/5 and my first Covid vaccination on 2/24!! Thanks to science, medical research, clinical trials, and luck, Iβve lived 9 1/2 yrs with stage 4 LC. Iβll get to see my son again soon! #LCSM |
 | Nathan A. Pennell MD, PhD, FASCO @n8pennell Nate Pennell in Cleveland! #lcsm |
| #LCSM Chat @lcsmchat @B32598085 Welcome! Thanks for joining. #lcsm |
| #LCSM Chat @lcsmchat @bjork5 Hey Dave! #lcsm |
| kristen kimball @KimballKristen RT @JFreemanDaily: Lecia Sequist, MD, MPH, (@LeciaSequist) is the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. https://t.co/fzqQxKbUwg #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| kristen kimball @KimballKristen RT @JFreemanDaily: Welcome to #LCSM Chat! Tonightβs chat will discuss βLiquid BxβIt pays to be vein.β (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g |
| #LCSM Chat @lcsmchat @MattSmeltzer Hi Matt! Welcome. #lcsm |
| Jill Feldman @jillfeldman4 RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @n8pennell Hi Nate! #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| Janet Freeman-Daily @JFreemanDaily Please remember to use #lcsm in all your tweets so others participating in the chat can see them. |
 | Adrian Sacher, M.D. @DocSacher RT @OncLive: Poziotinib Shows Meaningful Activity in EGFR Exon 20βMutant NSCLC @DocSacher @pmcancercentre #lcsm https://t.co/9RsBmZhl6h |
 | Patty Watkins @Pattybeatslungc RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| #LCSM Chat @lcsmchat @EricBernicker Hi Eric! Weβll have to compare our fave Dead songs one day. #lcsm |
| Janet Freeman-Daily @JFreemanDaily If you prefer just to listen, please tweet β#LCSMβ so we know youβre in the audience. However, if you want to jump in, feel free -- we're a friendly bunch! |
 | Luis E Raez @LuisERaez1 RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| Triage Cancer @TriageCancer RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| Janet Freeman-Daily @JFreemanDaily Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/A2M7gXQ66L) will not display tweets longer than 140. #lcsm |
| #LCSM Chat @lcsmchat Welcome! Remember to include the hashtag #lcsm in all your tweets so we can see them during the chat. |
| Kristin Ito @KAdvocate_LCAM RT @JFreemanDaily: Please remember to use #lcsm in all your tweets so others participating in the chat can see them. |
| Erika Hlavacek @ErikaHlavacek RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
 | Nirmal Raut @oncologician RT @LeciaSequist: I'm excited about #LCSM chat tonight! The wonderful @CharuAggarwalMD and I will be discussing liquid biopsies. Starting in a few minutes! Come join us. Thank you @JFreemanDaily for the invitation! |
| #LCSM Chat @lcsmchat @debsmithbeach Yay! Great news, Deb. #lcsm |
| Eric Bernicker @EricBernicker Absolutely! |
| #LCSM Chat @lcsmchat @n8pennell Hi Nate! #lcsm |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| Janet Freeman-Daily @JFreemanDaily #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Please remember to use #lcsm in all your tweets so others participating in the chat can see them. |
| Nirmal Raut @oncologician RT @JFreemanDaily: Welcome to #LCSM Chat! Tonightβs chat will discuss βLiquid BxβIt pays to be vein.β (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: If you prefer just to listen, please tweet β#LCSMβ so we know youβre in the audience. However, if you want to jump in, feel free -- we're a friendly bunch! |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Note: Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/A2M7gXQ66L) will not display tweets longer than 140. #lcsm |
| kristen kimball @KimballKristen @debsmithbeach #LCSM I'm glad to hear this, Deb :) |
 | Christian Rolfo @ChristianRolfo @CharuAggarwalMD @lcsmchat Sorry I forgot #LCSM ! |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily I will announce FOUR topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #lcsm |
 | Mia Spano-Curtiss & Sondra Price @BSBreastCancer RT @RedGia: Gia here from NC. Stage IV lung cancer since 9/2014. Looking forward to this discussion. #lcsm |
| #LCSM Chat @lcsmchat @CharuAggarwalMD We still love you. #lcsm |
| Janet Freeman-Daily @JFreemanDaily T1. What are the different methods of liquid biopsy (liquid Bx)? What are the advantages and pitfalls of each? #lcsm |
 | Renee Parker @Traveldoc33 @JFreemanDaily @lcsmchat #LCSM First time participant. Looking forward to it. I am a retired OB/GYN thanks to lung cancer and now am a patient advocate. |
| Lecia Sequist, MD, MPH @LeciaSequist T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I will announce FOUR topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #lcsm |
| Luis E Raez @LuisERaez1 Agree and also i think they are many more potential indications of liquid biopsies than doing molecular dx for metastatic disease, we need to move to: monitor response, detection of recurrence and ultimately cancer diagnosis. @isliquidbiopsy @FLASCO_ORG @MCIStrong @mhshospital |
| Jill Feldman @jillfeldman4 RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T1. What are the different methods of liquid biopsy (liquid Bx)? What are the advantages and pitfalls of each? #lcsm |
| Erika Hlavacek @ErikaHlavacek RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| #LCSM Chat @lcsmchat @Traveldoc33 @JFreemanDaily Hey Renee! Welcome. #lcsm |
 | Peggy Dennis @peggyddennis Peggy joining from Denver. Hi all! #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T1: T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM Mia from #BSBC here! Good evening everyone thanks @RedGia for the invite! |
| Lecia Sequist, MD, MPH @LeciaSequist @ChristianRolfo @CharuAggarwalMD @FDAOncology @GuardantHealth @FoundationATCG This paradigm plays out over and over across oncology.... #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @LeciaSequist: T1: T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T1. The most commonly used β#LiquidBiopsyβ approach in clinical practice today relies on analysis of circulating tumor DNA, βshedβ fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu |
| Lecia Sequist, MD, MPH @LeciaSequist T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| #LCSM Chat @lcsmchat @peggyddennis Hi Peggy! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @LeciaSequist What are CTCs, ctDNA, exosomes and RNA? #LCSM |
| #LCSM Chat @lcsmchat @BSBreastCancer @RedGia Welcome! So glad youβve joined us. #lcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM #LiquidBiopsy #cancer |
| Erika Hlavacek @ErikaHlavacek RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM |
 | Sophia Kamran, MD @sophia_kamran RT @HenningWillers: @dr_jonathant @DrChowdharyMD @XRT4U @SorenBentzen 1/n Yeah that data may go in a similar direction. Ok so here is what we are thinking regarding optimal esophagus sparing with IMRT and the question of BID vs QD ... Presented by @sophia_kamran at #ASTRO20 @ASTRO_org https://t.co/C9FFnHQFmo Paper will come out next month |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM |
| kristen kimball @KimballKristen RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T1. The most commonly used β#LiquidBiopsyβ approach in clinical practice today relies on analysis of circulating tumor DNA, βshedβ fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu |
 | Denise Cutlip @dennycee @lcsmchat @peggyddennis Hi, Peggy. Happy to see you. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @LeciaSequist What are CTCs, ctDNA, exosomes and RNA? #LCSM |
| Jill Feldman @jillfeldman4 RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T1: T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM |
| Jill Feldman @jillfeldman4 RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM |
| Erika Hlavacek @ErikaHlavacek RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T1: T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM |
| Denise Cutlip @dennycee RT @JFreemanDaily: @LeciaSequist What are CTCs, ctDNA, exosomes and RNA? #LCSM |
 | Dr. Amy C. Moore @acmoorephd This is Amy Moore, Director of Science & Research for @GO2Foundation. Glad to be with y'all tonight and to learn more from two of my LC heroes, @CharuAggarwalMD and @LeciaSequist, about the power of liquid biopsies! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T1. The most commonly used β#LiquidBiopsyβ approach in clinical practice today relies on analysis of circulating tumor DNA, βshedβ fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T1: An advantage for liq bx - they are less invasive/just a blood draw! However, you may not find material and a negative test does not prove "absence". As @dave6408 once said, not catching a fish doesn't mean the lake is empty. #LCSM https://t.co/skiLuQ96bP |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM this is very good information and quite understandable ... |
| Christian Rolfo @ChristianRolfo #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @JFreemanDaily @LeciaSequist CTCs are circulating tumor cells, which are wandering tumor cells trying to find new homes. ctDNA is circulating Tumor DNA, which is most commonly used for plasma NGS assessment #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T1: T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM |
| Erika Hlavacek @ErikaHlavacek RT @LeciaSequist: T1: T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T1: T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T1. Evaluation of #ctDNA can be performed for single genes (e.g. #EGFR) alone or multi-panel testing-for many mutations at once. Single gene testing is often fast and cost-effective. Adding in a large panel can increase cost and turnaround time #LCSM |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM most commonly used #LiquidBiopsy read below |
 | Geoff Oxnard MD @geoff_oxnard RT @lcsmchat: #LCSM Chat TODAY! Read more here: https://t.co/gyQSlR80sC⦠New to tweet chats? Read this primer: #LCSM Chat TODAY! Read more here: https://t.co/gyQSlR80sC⦠New to tweet chats? Read this primer: https://t.co/6MLl8di4X5 Join @JFreemanDaily @CharuAggarwalMD @LeciaSequist tonight at 8pm ET, 5pm PT for this *ALL* CANCERS CHAT! #hcsm https://t.co/qeK4pi4JlI |
| Dr. Amy C. Moore @acmoorephd RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM |
| #LCSM Chat @lcsmchat @acmoorephd @GO2Foundation @CharuAggarwalMD @LeciaSequist Hi Amy! #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T1: T1: An advantage for liq bx - they are less invasive/just a blood draw! However, you may not find material and a negative test does not prove "absence". As @dave6408 once said, not catching a fish doesn't mean the lake is empty. #LCSM https://t.co/skiLuQ96bP |
| Janet Freeman-Daily @JFreemanDaily @BSBreastCancer You might want to retweet with #BCSM to share these tweets with your cancer community. The tweets already contain #LCSM. |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM |
| Dr. Amy C. Moore @acmoorephd @lcsmchat @GO2Foundation @CharuAggarwalMD @LeciaSequist Good evening! #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD I love this graphic on a negative #LiquidBiopsy doesn't mean that it is truly negative #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: This is Amy Moore, Director of Science & Research for @GO2Foundation. Glad to be with y'all tonight and to learn more from two of my LC heroes, @CharuAggarwalMD and @LeciaSequist, about the power of liquid biopsies! #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: T1. The most commonly used β#LiquidBiopsyβ approach in clinical practice today relies on analysis of circulating tumor DNA, βshedβ fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: #lcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist CTCs are circulating tumor cells, which are wandering tumor cells trying to find new homes. ctDNA is circulating Tumor DNA, which is most commonly used for plasma NGS assessment #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T1. Evaluation of #ctDNA can be performed for single genes (e.g. #EGFR) alone or multi-panel testing-for many mutations at once. Single gene testing is often fast and cost-effective. Adding in a large panel can increase cost and turnaround time #LCSM |
| Jill Feldman @jillfeldman4 #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T1: T1: An advantage for liq bx - they are less invasive/just a blood draw! However, you may not find material and a negative test does not prove "absence". As @dave6408 once said, not catching a fish doesn't mean the lake is empty. #LCSM https://t.co/skiLuQ96bP |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: I love this graphic on a negative #LiquidBiopsy doesn't mean that it is truly negative #LCSM |
| Jill Feldman @jillfeldman4 #LCSM |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM |
| Matthew Smeltzer @MattSmeltzer RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: I love this graphic on a negative #LiquidBiopsy doesn't mean that it is truly negative #LCSM |
| Nirmal Raut @oncologician @CharuAggarwalMD Is doing NGS from CTC better than cfDNA ? #LCSM |
| #LCSM Chat @lcsmchat RT @oncologician: @CharuAggarwalMD Is doing NGS from CTC better than cfDNA ? #LCSM |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: T1. Evaluation of #ctDNA can be performed for single genes (e.g. #EGFR) alone or multi-panel testing-for many mutations at once. Single gene testing is often fast and cost-effective. Adding in a large panel can increase cost and turnaround time #LCSM |
| Janet Freeman-Daily @JFreemanDaily Love this analogy for liquid biopsies! "Not catching a fish doesn't mean the lake is empty." #lcsm |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist CTCs are circulating tumor cells, which are wandering tumor cells trying to find new homes. ctDNA is circulating Tumor DNA, which is most commonly used for plasma NGS assessment #LCSM |
| Danielle Pardue @Actorielle RT @ChristianRolfo: #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: #lcsm |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist CTCs are circulating tumor cells, which are wandering tumor cells trying to find new homes. ctDNA is circulating Tumor DNA, which is most commonly used for plasma NGS assessment #LCSM |
| Danielle Pardue @Actorielle RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu |
 | Lisa Briggs @livinglife82 Hello from Melbourne #Australia @lcsmchat looking forward to all things #liquidbiopsy #LCSM |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: T1. The most commonly used β#LiquidBiopsyβ approach in clinical practice today relies on analysis of circulating tumor DNA, βshedβ fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T1. Evaluation of #ctDNA can be performed for single genes (e.g. #EGFR) alone or multi-panel testing-for many mutations at once. Single gene testing is often fast and cost-effective. Adding in a large panel can increase cost and turnaround time #LCSM |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer RT @lcsmchat: @BSBreastCancer @RedGia Welcome! So glad youβve joined us. #lcsm |
| Danielle Pardue @Actorielle RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM |
| Kristin Ito @KAdvocate_LCAM T1. Similar to biomarker testing, with liquid biopsy do you have to be selective for what you are testing for? #LCSM #AlwaysLearning |
| Danielle Pardue @Actorielle RT @LeciaSequist: T1: T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM |
| Danielle Pardue @Actorielle RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG |
| Christian Rolfo @ChristianRolfo @JFreemanDaily @LeciaSequist Exosomes ( extra cellular vesicles) are a good tool to understand different biological process in cancer . Currently used as prognostic biomarkers (in research) for IO for example #lcsm @IsevOrg @islb @ddemiguelperez |
| #LCSM Chat @lcsmchat @livinglife82 Hi Lisa! Belated Happy Birthday. #lcsm |
| Jill Feldman @jillfeldman4 Just because you don't catch a fish, it doesn't mean the lake is empty! #LCSM |
| Dr. Amy C. Moore @acmoorephd It was a thrill and an honor to be part of this episode of @IASLC's "Lung Cancer Considered" podcast with two of the brightest minds in #lungcancer research, Drs. Paul Bunn and @StephenVLiu, and @moderna_tx's CMO, Dr. Tal Zaks! Listen to it March 8! #lcsm |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG |
| Dr. Amy C. Moore @acmoorephd @CharuAggarwalMD @lcsmchat @GO2Foundation @LeciaSequist Hi! #lcsm |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM #BCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD ctMONITR is an excellent example of how we need to pool resources to study the importance of serial ctDNA changes in #NSCLC #LCSM |
| Kristin Ito @KAdvocate_LCAM @CharuAggarwalMD I think you answered my question in your recent post! #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T1. I find that plasma #NGS testing of #ctDNA is timely (with turnaround time of 7-14 days), however can miss mutations in case of low overall tumor burden or low βshedβ #LCSM |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: T1. Similar to biomarker testing, with liquid biopsy do you have to be selective for what you are testing for? #LCSM #AlwaysLearning |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM #BCSM |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: @JFreemanDaily @LeciaSequist Exosomes ( extra cellular vesicles) are a good tool to understand different biological process in cancer . Currently used as prognostic biomarkers (in research) for IO for example #lcsm @IsevOrg @islb @ddemiguelperez |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer RT @acmoorephd: @CharuAggarwalMD @lcsmchat @GO2Foundation @LeciaSequist Hi! #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @KAdvocate_LCAM Yes, just like testing tumors you have to order the test that contains the info you are looking for and also be aware of what the test cannot do #LCSM |
| Janet Freeman-Daily @JFreemanDaily @oncologician @CharuAggarwalMD In many cancers, cfDNA is more plentiful in the blood than CTC, so you have a better chance of an accurate test result with cfDNA in most cases. #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: ctMONITR is an excellent example of how we need to pool resources to study the importance of serial ctDNA changes in #NSCLC #LCSM |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer @acmoorephd @IASLC @StephenVLiu @moderna_tx #LCSM #BCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T1. I find that plasma #NGS testing of #ctDNA is timely (with turnaround time of 7-14 days), however can miss mutations in case of low overall tumor burden or low βshedβ #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @KAdvocate_LCAM Yes, just like testing tumors you have to order the test that contains the info you are looking for and also be aware of what the test cannot do #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @oncologician @CharuAggarwalMD In many cancers, cfDNA is more plentiful in the blood than CTC, so you have a better chance of an accurate test result with cfDNA in most cases. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @KAdvocate_LCAM: T1. Similar to biomarker testing, with liquid biopsy do you have to be selective for what you are testing for? #LCSM #AlwaysLearning |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer Happy Birthday Lisa from #BSBC |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM #BCSM |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: @JFreemanDaily @LeciaSequist Exosomes ( extra cellular vesicles) are a good tool to understand different biological process in cancer . Currently used as prognostic biomarkers (in research) for IO for example #lcsm @IsevOrg @islb @ddemiguelperez |
| Lecia Sequist, MD, MPH @LeciaSequist @JFreemanDaily @oncologician @CharuAggarwalMD I agree with Janet. CTC assays are not reliable enough yet, or widely available enough to do clinical genotyping for selection of targeted therapy. This is ctDNA's strongest niche! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: ctMONITR is an excellent example of how we need to pool resources to study the importance of serial ctDNA changes in #NSCLC #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195 |
| Lecia Sequist, MD, MPH @LeciaSequist T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T1. I find that plasma #NGS testing of #ctDNA is timely (with turnaround time of 7-14 days), however can miss mutations in case of low overall tumor burden or low βshedβ #LCSM |
| Danielle Pardue @Actorielle RT @LeciaSequist: @JFreemanDaily @oncologician @CharuAggarwalMD I agree with Janet. CTC assays are not reliable enough yet, or widely available enough to do clinical genotyping for selection of targeted therapy. This is ctDNA's strongest niche! #LCSM |
| Janet Freeman-Daily @JFreemanDaily T2. How might liquid Bx be used for treatment monitoring and detecting disease progression? #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @JFreemanDaily @oncologician @CharuAggarwalMD I agree with Janet. CTC assays are not reliable enough yet, or widely available enough to do clinical genotyping for selection of targeted therapy. This is ctDNA's strongest niche! #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195 |
| Jill Feldman @jillfeldman4 RT @CharuAggarwalMD: T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195 |
| Danielle Pardue @Actorielle RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @KAdvocate_LCAM Yes, just like testing tumors you have to order the test that contains the info you are looking for and also be aware of what the test cannot do #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T2. How might liquid Bx be used for treatment monitoring and detecting disease progression? #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @JFreemanDaily @oncologician @CharuAggarwalMD I agree with Janet. CTC assays are not reliable enough yet, or widely available enough to do clinical genotyping for selection of targeted therapy. This is ctDNA's strongest niche! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195 |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl |
| Kristin Ito @KAdvocate_LCAM RT @JFreemanDaily: T2. How might liquid Bx be used for treatment monitoring and detecting disease progression? #lcsm |
| kristen kimball @KimballKristen RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk |
| Jill Feldman @jillfeldman4 RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk |
| Dave Bjork @bjork5 #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk |
| Danielle Pardue @Actorielle RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM #BCSM |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| Jill Feldman @jillfeldman4 #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s |
| Lecia Sequist, MD, MPH @LeciaSequist T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe |
| Kristin Ito @KAdvocate_LCAM T2. If this is beneficial, are there major cost barriers to be considerate of? Insurance is a beast. #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe |
| Eric Bernicker @EricBernicker Most platforms will test for a panel of common mutations. ( Fortunately for most oncologists you don't need to specify every mutation you are looking for 0 #LCSM |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s |
| Danielle Pardue @Actorielle RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe |
| Janet Freeman-Daily @JFreemanDaily @LeciaSequist @RamalingamMD So if you don't see ctDNA after #cancer treatment, it's a good chance the treatment worked well? #LCSM |
| Lisa Briggs @livinglife82 T1: From a #patient perspective Pros - minimally invasive, easy to perform, more pleasant experience than trad. biopsy Cons - Treatments are NOT subsidized in π¦πΊ following a #liquidbiopsy, if progression is in the brain high levels of ctDNA are required to obtain info #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T2. Another biomarker that can be assessed using plasma ctDNA is #TMB #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T2: One thing we aren't sure of yet is when/if/how to react to a resistance mechanism found on ctDNA in the absence of radiographic or symptomatic progression. Prospective trials are needed! #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe |
| Dr. Amy C. Moore @acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD I got asked about use of liquid Bx for #SCLC the other day. Do CTCs come more into play in this setting? #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s |
| Jill Feldman @jillfeldman4 #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s |
| #LCSM Chat @lcsmchat RT @KAdvocate_LCAM: T2. If this is beneficial, are there major cost barriers to be considerate of? Insurance is a beast. #LCSM |
| #LCSM Chat @lcsmchat RT @EricBernicker: Most platforms will test for a panel of common mutations. ( Fortunately for most oncologists you don't need to specify every mutation you are looking for 0 #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe |
| Erika Hlavacek @ErikaHlavacek RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @LeciaSequist @RamalingamMD So if you don't see ctDNA after #cancer treatment, it's a good chance the treatment worked well? #LCSM |
 | Sanjay Mukhopadhyay @smlungpathguy Tweet of the day ππΎπ₯ This is the best line ever to use when a βproceduralistβ asks you how it can be that their biopsy doesnβt have diagnostic material. βNOT CATCHING A FISH DOESNβT MEAN THE LAKE IS EMPTYβ |
| #LCSM Chat @lcsmchat RT @livinglife82: T1: T1: From a #patient perspective Pros - minimally invasive, easy to perform, more pleasant experience than trad. biopsy Cons - Treatments are NOT subsidized in π¦πΊ following a #liquidbiopsy, if progression is in the brain high levels of ctDNA are required to obtain info #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T2. Another biomarker that can be assessed using plasma ctDNA is #TMB #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T2: T2: One thing we aren't sure of yet is when/if/how to react to a resistance mechanism found on ctDNA in the absence of radiographic or symptomatic progression. Prospective trials are needed! #LCSM |
| #LCSM Chat @lcsmchat RT @acmoorephd: @LeciaSequist @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD I got asked about use of liquid Bx for #SCLC the other day. Do CTCs come more into play in this setting? #lcsm |
| Lisa Briggs @livinglife82 RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T2. Tumor gene mutation burden (TMB) is the approx amount of gene mutations that occur in the a cancer cell. Usually measured using whole genome sequencing, we can get it with plasma #NGS panels @drgandara @VamsiVelcheti https://t.co/VPTrvHKVWW https://t.co/PIxa6K8CGD #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T2. Tumor gene mutation burden (TMB) is the approx amount of gene mutations that occur in the a cancer cell. Usually measured using whole genome sequencing, we can get it with plasma #NGS panels @drgandara @VamsiVelcheti https://t.co/VPTrvHKVWW https://t.co/PIxa6K8CGD #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @JFreemanDaily @LeciaSequist @RamalingamMD Likely. Clinical trials are now ongoing to escalate therapy for those with persistent ctDNA. I think this will be a valuable resource in the future #LCSM |
| Christian Rolfo @ChristianRolfo @LeciaSequist @RamalingamMD This is an important concept we see using in monitoring. In addition of the dynamic of VAF, agood prognostic biomarker in immuno and targeted therapies. #lcsm @isliquidbiopsy |
 | Michael Kelley, MD @kelleymic #VACancerCare @VeteransHealth @DeptVetAffairs @VAResearch |
| Janet Freeman-Daily @JFreemanDaily @KAdvocate_LCAM The applications of #liquidbiopsy that @CharuAggarwalMD and @LeciaSequist are discussion in the chat are still in development. So far, only liquid bx test approved is to identify specific genomic drivers (biomarkers) in #lungcancer. #LCSM |
| Lisa Briggs @livinglife82 RT @CharuAggarwalMD: T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG |
| Janet Freeman-Daily @JFreemanDaily RT @KAdvocate_LCAM: T2. If this is beneficial, are there major cost barriers to be considerate of? Insurance is a beast. #LCSM |
| Jill Feldman @jillfeldman4 This is definitely an unmet need. It is anxiety-provoking for patients, and I'm sure oncs as well. #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist @RamalingamMD Likely. Clinical trials are now ongoing to escalate therapy for those with persistent ctDNA. I think this will be a valuable resource in the future #LCSM |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: @LeciaSequist @RamalingamMD This is an important concept we see using in monitoring. In addition of the dynamic of VAF, agood prognostic biomarker in immuno and targeted therapies. #lcsm @isliquidbiopsy |
 | Liz Szabo @LizSzabo RT @BSBreastCancer: Who's joining in for the #LCSM Chat tonight? All Cancers Chat #bcsm #btsm #ayacsm #gyncsm #orosm #Pcsm @LizSzabo |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @KAdvocate_LCAM The applications of #liquidbiopsy that @CharuAggarwalMD and @LeciaSequist are discussion in the chat are still in development. So far, only liquid bx test approved is to identify specific genomic drivers (biomarkers) in #lungcancer. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: Most platforms will test for a panel of common mutations. ( Fortunately for most oncologists you don't need to specify every mutation you are looking for 0 #LCSM |
| #LCSM Chat @lcsmchat RT @jillfeldman4: This is definitely an unmet need. It is anxiety-provoking for patients, and I'm sure oncs as well. #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell @CharuAggarwalMD @JFreemanDaily @LeciaSequist @RamalingamMD Yes the ability to intervene in high risk patients is key, otherwise itβs not that helpful to know a worse prognosis! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist @RamalingamMD Likely. Clinical trials are now ongoing to escalate therapy for those with persistent ctDNA. I think this will be a valuable resource in the future #LCSM |
| Erika Hlavacek @ErikaHlavacek #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: @CharuAggarwalMD @JFreemanDaily @LeciaSequist @RamalingamMD Yes the ability to intervene in high risk patients is key, otherwise itβs not that helpful to know a worse prognosis! #lcsm |
| Eric Bernicker @EricBernicker Financial toxicity is always a concern but most test are covered, certainly at diagnosis. But the real financial toxicity would be missing an actionable mutation and getting expensive and possibly ineffective immunotherapy ...#LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician CTCs are more plentiful in SCLC than SCLC, and we have had some experience with genotyping SCLC CTCs successfully. Again, more research based at this time #LCSM |
| #LCSM Chat @lcsmchat #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @livinglife82: T1: T1: From a #patient perspective Pros - minimally invasive, easy to perform, more pleasant experience than trad. biopsy Cons - Treatments are NOT subsidized in π¦πΊ following a #liquidbiopsy, if progression is in the brain high levels of ctDNA are required to obtain info #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T2. Another biomarker that can be assessed using plasma ctDNA is #TMB #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T2: T2: One thing we aren't sure of yet is when/if/how to react to a resistance mechanism found on ctDNA in the absence of radiographic or symptomatic progression. Prospective trials are needed! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: @LeciaSequist @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD I got asked about use of liquid Bx for #SCLC the other day. Do CTCs come more into play in this setting? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T2. Tumor gene mutation burden (TMB) is the approx amount of gene mutations that occur in the a cancer cell. Usually measured using whole genome sequencing, we can get it with plasma #NGS panels @drgandara @VamsiVelcheti https://t.co/VPTrvHKVWW https://t.co/PIxa6K8CGD #LCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: @CharuAggarwalMD @JFreemanDaily @LeciaSequist @RamalingamMD Yes the ability to intervene in high risk patients is key, otherwise itβs not that helpful to know a worse prognosis! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: @LeciaSequist @RamalingamMD This is an important concept we see using in monitoring. In addition of the dynamic of VAF, agood prognostic biomarker in immuno and targeted therapies. #lcsm @isliquidbiopsy |
| #LCSM Chat @lcsmchat RT @EricBernicker: Financial toxicity is always a concern but most test are covered, certainly at diagnosis. But the real financial toxicity would be missing an actionable mutation and getting expensive and possibly ineffective immunotherapy ...#LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician CTCs are more plentiful in SCLC than SCLC, and we have had some experience with genotyping SCLC CTCs successfully. Again, more research based at this time #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: This is definitely an unmet need. It is anxiety-provoking for patients, and I'm sure oncs as well. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @EricBernicker: Financial toxicity is always a concern but most test are covered, certainly at diagnosis. But the real financial toxicity would be missing an actionable mutation and getting expensive and possibly ineffective immunotherapy ...#LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @EricBernicker: Financial toxicity is always a concern but most test are covered, certainly at diagnosis. But the real financial toxicity would be missing an actionable mutation and getting expensive and possibly ineffective immunotherapy ...#LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician CTCs are more plentiful in SCLC than SCLC, and we have had some experience with genotyping SCLC CTCs successfully. Again, more research based at this time #LCSM |
 | Christina Lizaso @btrfly12 RT @jillfeldman4: Just because you don't catch a fish, it doesn't mean the lake is empty! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @lcsmchat: #lcsm |
 | MaryAnn Bradley @Dollybrad RT @Kamacintosh: TY @DoctorJSpicer for supporting our movement as it spreads across North America! @TWRP Canada is Coast to Coast. We appreciate your support to #LungCancer community in Raising #Awareness 4 #1 #Cancer Killer #TheWhiteRibbonProject #LCSM #AllYouNeedIsLungs #AnyoneCanGetLungCancer https://t.co/vcMYvAym1z |
| Lecia Sequist, MD, MPH @LeciaSequist @JFreemanDaily @RamalingamMD This assumption is predicated on the fact that there WAS detectable ctDNA w/ the same assay before therapy. If not detectable pre-rx, can't follow conversion to undetectable as a potential biomarker #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @JFreemanDaily @RamalingamMD This assumption is predicated on the fact that there WAS detectable ctDNA w/ the same assay before therapy. If not detectable pre-rx, can't follow conversion to undetectable as a potential biomarker #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @JFreemanDaily @RamalingamMD This assumption is predicated on the fact that there WAS detectable ctDNA w/ the same assay before therapy. If not detectable pre-rx, can't follow conversion to undetectable as a potential biomarker #LCSM |
| Christina Lizaso @btrfly12 RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu |
| Christian Rolfo @ChristianRolfo #lcsm |
| Janet Freeman-Daily @JFreemanDaily #LCSM |
| Lisa Briggs @livinglife82 T2 - Is the sensitivity of detecting disease progression through #liquidbiopsy highly dependent on the region progression has occurred. Eg more likely to detect it if itβs in the lung vs brain or bone. OR is it largely based on the turnover of cells shedding? #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r |
| Janet Freeman-Daily @JFreemanDaily T3. How might liquid Bx be used for prognosis or to measure cancer remaining after treatment? #lcsm |
| Triage Cancer @TriageCancer @JFreemanDaily @KAdvocate_LCAM @CharuAggarwalMD @LeciaSequist There are free resources about navigating health insurance, health insurance appeals, and other issues related to payment for various biomarker tests at our website: https://t.co/zY7CesHqJn and also https://t.co/5IxhJu4Y0S #lcsm |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: #lcsm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: Welcome to #LCSM Chat! Tonightβs chat will discuss βLiquid BxβIt pays to be vein.β (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g |
| #LCSM Chat @lcsmchat RT @livinglife82: T2 - Is the sensitivity of detecting disease progression through #liquidbiopsy highly dependent on the region progression has occurred. Eg more likely to detect it if itβs in the lung vs brain or bone. OR is it largely based on the turnover of cells shedding? #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T3: T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T3. How might liquid Bx be used for prognosis or to measure cancer remaining after treatment? #lcsm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: T3. How might liquid Bx be used for prognosis or to measure cancer remaining after treatment? #lcsm |
| #LCSM Chat @lcsmchat RT @TriageCancer: @JFreemanDaily @KAdvocate_LCAM @CharuAggarwalMD @LeciaSequist There are free resources about navigating health insurance, health insurance appeals, and other issues related to payment for various biomarker tests at our website: https://t.co/zY7CesHqJn and also https://t.co/5IxhJu4Y0S #lcsm |
| Dr. Amy C. Moore @acmoorephd RT @CharuAggarwalMD: @acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician CTCs are more plentiful in SCLC than SCLC, and we have had some experience with genotyping SCLC CTCs successfully. Again, more research based at this time #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @ErikaHlavacek: #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T3. The concept of βminimal residual diseaseβ has been traditionally used in leukemia. Relies on the detection of remaining ctDNA to detect high risk individuals that may still have circulating disease burden that can be targeted for additional therapy! @max_diehn #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T3: A key point is that we need to conduct prospective clinical trials before using MRD markers to guide therapy. We need to prove that such guided strategies improve outcomes #LCSM |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: @KAdvocate_LCAM The applications of #liquidbiopsy that @CharuAggarwalMD and @LeciaSequist are discussion in the chat are still in development. So far, only liquid bx test approved is to identify specific genomic drivers (biomarkers) in #lungcancer. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @livinglife82: T2 - Is the sensitivity of detecting disease progression through #liquidbiopsy highly dependent on the region progression has occurred. Eg more likely to detect it if itβs in the lung vs brain or bone. OR is it largely based on the turnover of cells shedding? #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T3: T3: A key point is that we need to conduct prospective clinical trials before using MRD markers to guide therapy. We need to prove that such guided strategies improve outcomes #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T3. The concept of βminimal residual diseaseβ has been traditionally used in leukemia. Relies on the detection of remaining ctDNA to detect high risk individuals that may still have circulating disease burden that can be targeted for additional therapy! @max_diehn #LCSM |
| Christina Lizaso @btrfly12 RT @CharuAggarwalMD: T2. Tumor gene mutation burden (TMB) is the approx amount of gene mutations that occur in the a cancer cell. Usually measured using whole genome sequencing, we can get it with plasma #NGS panels @drgandara @VamsiVelcheti https://t.co/VPTrvHKVWW https://t.co/PIxa6K8CGD #LCSM |
 | Coach Duff @CoachDuff RT @bjork5: Hi friends, Dave Bjork here in Boston, host of the https://t.co/WePGnEdkmc #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @livinglife82 Great question and both have shown to correlate w/ more ctDNA. It's a combo of biology of tumor, location/ amount of mets, and sensitivity of the assay. A positive test is informative, but a negative test is not that useful. (see fish picture again !) #LCSM https://t.co/zf258X44Am |
| Janet Freeman-Daily @JFreemanDaily @livinglife82 My understanding: at present, #liquidbiopsy is not effective at detecting cancer or other biomarkers in the brain. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T3: T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r |
| Kristin Ito @KAdvocate_LCAM RT @LeciaSequist: T3: T3: A key point is that we need to conduct prospective clinical trials before using MRD markers to guide therapy. We need to prove that such guided strategies improve outcomes #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @livinglife82 Great question and both have shown to correlate w/ more ctDNA. It's a combo of biology of tumor, location/ amount of mets, and sensitivity of the assay. A positive test is informative, but a negative test is not that useful. (see fish picture again !) #LCSM https://t.co/zf258X44Am |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T3: T3: A key point is that we need to conduct prospective clinical trials before using MRD markers to guide therapy. We need to prove that such guided strategies improve outcomes #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @livinglife82 My understanding: @livinglife82 My understanding: at present, #liquidbiopsy is not effective at detecting cancer or other biomarkers in the brain. #LCSM |
| Christian Rolfo @ChristianRolfo @JFreemanDaily #lcsm MRD is a great scenario for research and her we can recuperate CTCs as a tool to detect disease after surgery like in this trial https://t.co/KozoaWb8Hn |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T3. The concept of βminimal residual diseaseβ has been traditionally used in leukemia. Relies on the detection of remaining ctDNA to detect high risk individuals that may still have circulating disease burden that can be targeted for additional therapy! @max_diehn #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell @LeciaSequist @max_diehn I think this will be the future of monitoring for recurrence after potentially curative treatment for cancer! again though ability to intervene when still positive is key #lcsm |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @LeciaSequist: T3: T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @livinglife82 Great question and both have shown to correlate w/ more ctDNA. It's a combo of biology of tumor, location/ amount of mets, and sensitivity of the assay. A positive test is informative, but a negative test is not that useful. (see fish picture again !) #LCSM https://t.co/zf258X44Am |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: @JFreemanDaily #lcsm MRD is a great scenario for research and her we can recuperate CTCs as a tool to detect disease after surgery like in this trial https://t.co/KozoaWb8Hn |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T3. We could apply the concept of βminimal residual diseaseβ to the setting of Early Stage #LungCancer and Locally Advanced #LungCancer to identify individuals with #ctDNA, who can be selected for additional therapy #LCSM https://t.co/kBTdPDGJJh |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: @JFreemanDaily #lcsm MRD is a great scenario for research and her we can recuperate CTCs as a tool to detect disease after surgery like in this trial https://t.co/KozoaWb8Hn |
| Mia Spano-Curtiss & Sondra Price @BSBreastCancer #LCSM #BCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: @LeciaSequist @max_diehn I think this will be the future of monitoring for recurrence after potentially curative treatment for cancer! again though ability to intervene when still positive is key #lcsm |
| Janet Freeman-Daily @JFreemanDaily @ChristianRolfo @ChristianRolfo Thanks for all your great tweets in tonight's #LCSM Chat! |
| Lecia Sequist, MD, MPH @LeciaSequist @oncologician @acmoorephd @lcsmchat @JFreemanDaily @CharuAggarwalMD @LaurenByersMD @triparnasen @christine_lovly @cbmeador Depends on the method that you are using to collect CTCs. Some methods are "rough" and break apart the CTCs, spilling contents. Others are "gentle" and keep cells whole. Also WBCs contaminating CTCs can raise the "noise" compared to "signal" and contribute CH findings #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell @LeciaSequist Have this planned in EA 5181 chemo radiation trial for stage 3 NSCLC and others too Iβm sure! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: @LeciaSequist @max_diehn I think this will be the future of monitoring for recurrence after potentially curative treatment for cancer! again though ability to intervene when still positive is key #lcsm |
 | Aliye Bricker @AliyeBricker @LeciaSequist @lcsmchat If a liquid biopsy does not show the presence of a new resistance mechanism (such as a gate keeper mutation or solvent front mutation) despite clear evidence of progression on imaging, is it worth pursuing a tissue biopsy from a site of disease progression? #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T3. We could apply the concept of βminimal residual diseaseβ to the setting of Early Stage #LungCancer and Locally Advanced #LungCancer to identify individuals with #ctDNA, who can be selected for additional therapy #LCSM https://t.co/kBTdPDGJJh |
| Lisa Briggs @livinglife82 RT @LeciaSequist: @livinglife82 Great question and both have shown to correlate w/ more ctDNA. It's a combo of biology of tumor, location/ amount of mets, and sensitivity of the assay. A positive test is informative, but a negative test is not that useful. (see fish picture again !) #LCSM https://t.co/zf258X44Am |
| Nirmal Raut @oncologician RT @LeciaSequist: @oncologician @acmoorephd @lcsmchat @JFreemanDaily @CharuAggarwalMD @LaurenByersMD @triparnasen @christine_lovly @cbmeador Depends on the method that you are using to collect CTCs. Some methods are "rough" and break apart the CTCs, spilling contents. Others are "gentle" and keep cells whole. Also WBCs contaminating CTCs can raise the "noise" compared to "signal" and contribute CH findings #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @oncologician @acmoorephd @lcsmchat @JFreemanDaily @CharuAggarwalMD @LaurenByersMD @triparnasen @christine_lovly @cbmeador Depends on the method that you are using to collect CTCs. Some methods are "rough" and break apart the CTCs, spilling contents. Others are "gentle" and keep cells whole. Also WBCs contaminating CTCs can raise the "noise" compared to "signal" and contribute CH findings #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: @LeciaSequist Have this planned in EA 5181 chemo radiation trial for stage 3 NSCLC and others too Iβm sure! #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T3. We could apply the concept of βminimal residual diseaseβ to the setting of Early Stage #LungCancer and Locally Advanced #LungCancer to identify individuals with #ctDNA, who can be selected for additional therapy #LCSM https://t.co/kBTdPDGJJh |
 | Arpan Patel @ArpanAshokPatel RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl |
 | Christine Lovly, MD, PhD @christine_lovly @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not βprime timeβ in the clinic yet. Stay tuned. #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @oncologician @acmoorephd @lcsmchat @JFreemanDaily @CharuAggarwalMD @LaurenByersMD @triparnasen @christine_lovly @cbmeador Depends on the method that you are using to collect CTCs. Some methods are "rough" and break apart the CTCs, spilling contents. Others are "gentle" and keep cells whole. Also WBCs contaminating CTCs can raise the "noise" compared to "signal" and contribute CH findings #LCSM |
| #LCSM Chat @lcsmchat RT @n8pennell: @LeciaSequist Have this planned in EA 5181 chemo radiation trial for stage 3 NSCLC and others too Iβm sure! #lcsm |
| Nirmal Raut @oncologician RT @LeciaSequist: T3: T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r |
| Lecia Sequist, MD, MPH @LeciaSequist @AliyeBricker @lcsmchat yes, yes, yes 100%! This is a really key point for anyone ordering a liquid biopsy to remember! #LCSM |
| #LCSM Chat @lcsmchat RT @AliyeBricker: @LeciaSequist @lcsmchat If a liquid biopsy does not show the presence of a new resistance mechanism (such as a gate keeper mutation or solvent front mutation) despite clear evidence of progression on imaging, is it worth pursuing a tissue biopsy from a site of disease progression? #LCSM |
| Dr. Amy C. Moore @acmoorephd I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: T3. We could apply the concept of βminimal residual diseaseβ to the setting of Early Stage #LungCancer and Locally Advanced #LungCancer to identify individuals with #ctDNA, who can be selected for additional therapy #LCSM https://t.co/kBTdPDGJJh |
| Upstage Lung Cancer @UpstageLungCanc RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm |
| #LCSM Chat @lcsmchat RT @christine_lovly: @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not βprime timeβ in the clinic yet. Stay tuned. #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @AliyeBricker @lcsmchat yes, yes, yes 100%! This is a really key point for anyone ordering a liquid biopsy to remember! #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp |
| #LCSM Chat @lcsmchat RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Excellent Initiative! #LCSM @GO2Foundation |
| Danielle Pardue @Actorielle RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp |
| Janet Freeman-Daily @JFreemanDaily @AliyeBricker @LeciaSequist @lcsmchat Liquid biopsy guidelines in #lungcancer acknowledge the possibility of false negatives. If the liquid bx is positive, then treat based on liquid bx results. If liquid bx is negative, try to test with tissue. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @AliyeBricker: @LeciaSequist @lcsmchat If a liquid biopsy does not show the presence of a new resistance mechanism (such as a gate keeper mutation or solvent front mutation) despite clear evidence of progression on imaging, is it worth pursuing a tissue biopsy from a site of disease progression? #LCSM |
| #LCSM Chat @lcsmchat #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @MGHCancerCenter π |
| Nirmal Raut @oncologician RT @christine_lovly: @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not βprime timeβ in the clinic yet. Stay tuned. #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp |
| Janet Freeman-Daily @JFreemanDaily RT @christine_lovly: @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not βprime timeβ in the clinic yet. Stay tuned. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @AliyeBricker @lcsmchat yes, yes, yes 100%! This is a really key point for anyone ordering a liquid biopsy to remember! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @AliyeBricker @LeciaSequist @lcsmchat Liquid biopsy guidelines in #lungcancer acknowledge the possibility of false negatives. If the liquid bx is positive, then treat based on liquid bx results. If liquid bx is negative, try to test with tissue. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp |
| Nirmal Raut @oncologician RT @LeciaSequist: T2: T2: One thing we aren't sure of yet is when/if/how to react to a resistance mechanism found on ctDNA in the absence of radiographic or symptomatic progression. Prospective trials are needed! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Excellent Initiative! #LCSM @GO2Foundation |
| Gia Sonata @RedGia RT @TriageCancer: @JFreemanDaily @KAdvocate_LCAM @CharuAggarwalMD @LeciaSequist There are free resources about navigating health insurance, health insurance appeals, and other issues related to payment for various biomarker tests at our website: https://t.co/zY7CesHqJn and also https://t.co/5IxhJu4Y0S #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @lcsmchat: #lcsm |
 | Ladi Akinboro @LadiAkinboro RT @FDAOncology: FDA granted regular approval to lorlatinib (Lorbrena, Pfizer) for metastatic ALK+ non-small cell lung cancer. FDA also approved the Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems) as a companion diagnostic for lorlatinib. #LCSM #NSCLC https://t.co/gcQF0Fin70 |
| Dr. Amy C. Moore @acmoorephd RT @christine_lovly: @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not βprime timeβ in the clinic yet. Stay tuned. #LCSM |
| Janet Freeman-Daily @JFreemanDaily #LCSM |
| #LCSM Chat @lcsmchat #lcsm |
| Christian Rolfo @ChristianRolfo @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o |
| Nirmal Raut @oncologician RT @JFreemanDaily: #LCSM |
| Dr. Amy C. Moore @acmoorephd RT @JFreemanDaily: @AliyeBricker @LeciaSequist @lcsmchat Liquid biopsy guidelines in #lungcancer acknowledge the possibility of false negatives. If the liquid bx is positive, then treat based on liquid bx results. If liquid bx is negative, try to test with tissue. #lcsm |
| Lisa Briggs @livinglife82 @lcsmchat Many thanks #LCSM |
| Christian Rolfo @ChristianRolfo #lcsm |
 | NCI Cancer Stats @NCICancerStats There were ~228,820 new cases of #LungCancer in the US last year. Use our Cancer Stat Facts sheet to learn more about this cancer: https://t.co/BVqvN4e1pm #LCSM https://t.co/mQXofmUlGZ |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @ChristianRolfo: @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @ChristianRolfo: #lcsm |
| Dr. Amy C. Moore @acmoorephd RT @ChristianRolfo: @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o |
 | Whetstine Lab @WhetstineLab RT @bjork5: Hi friends, Dave Bjork here in Boston, host of the https://t.co/WePGnEdkmc #LCSM |
| Janet Freeman-Daily @JFreemanDaily The tweets in tonight's #lcsm chat on liquid biopsies have been fast and furious! Lots to unpack. Don't be afraid to ask questions. If we don't answer yours during the chat, we'll try to answer it after. |
| Erika Hlavacek @ErikaHlavacek I had innumerable brain mets and systemic progression & liquid biopsy showed nothing. Tissue saved the day. #lcsm |
| #LCSM Chat @lcsmchat #lcsm |
| #LCSM Chat @lcsmchat RT @ErikaHlavacek: I had innumerable brain mets and systemic progression & liquid biopsy showed nothing. Tissue saved the day. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: The tweets in tonight's #lcsm chat on liquid biopsies have been fast and furious! Lots to unpack. Don't be afraid to ask questions. If we don't answer yours during the chat, we'll try to answer it after. |
| Upstage Lung Cancer @UpstageLungCanc RT @JFreemanDaily: The tweets in tonight's #lcsm chat on liquid biopsies have been fast and furious! Lots to unpack. Don't be afraid to ask questions. If we don't answer yours during the chat, we'll try to answer it after. |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @ErikaHlavacek: I had innumerable brain mets and systemic progression & liquid biopsy showed nothing. Tissue saved the day. #lcsm |
| Jill Feldman @jillfeldman4 RT @ErikaHlavacek: I had innumerable brain mets and systemic progression & liquid biopsy showed nothing. Tissue saved the day. #lcsm |
| Kristin Ito @KAdvocate_LCAM @JFreemanDaily So grateful for this safe space to learn! #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @ErikaHlavacek Liquid biopsies rely on the amount of "shed" DNA into the bloodstream, therefore, it is important to always use tissue NGS in case of negatives #LCSM |
| Janet Freeman-Daily @JFreemanDaily @LeciaSequist @CharuAggarwalMD @ChristianRolfo Does cfDNA cross the blood-brain barrier? Can #liquidbiopsy be used to detect cancer in the brain? #LCSM |
| Danielle Pardue @Actorielle RT @KAdvocate_LCAM: @JFreemanDaily So grateful for this safe space to learn! #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @ErikaHlavacek Liquid biopsies rely on the amount of "shed" DNA into the bloodstream, therefore, it is important to always use tissue NGS in case of negatives #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @lcsmchat: #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @LeciaSequist @CharuAggarwalMD @ChristianRolfo Does cfDNA cross the blood-brain barrier? Can #liquidbiopsy be used to detect cancer in the brain? #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @ErikaHlavacek Liquid biopsies rely on the amount of "shed" DNA into the bloodstream, therefore, it is important to always use tissue NGS in case of negatives #LCSM |
| Danielle Pardue @Actorielle RT @ChristianRolfo: #lcsm |
| Janet Freeman-Daily @JFreemanDaily I've been so fascinated with all the tweets that I'm having trouble keeping track of time! BAD moderator. Topic T4 is coming up β¦ #lcsm |
| Dave Bjork @bjork5 #lcsm |
| Janet Freeman-Daily @JFreemanDaily T4. How might liquid biopsy be used for early detection of cancer? #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @JFreemanDaily @CharuAggarwalMD @ChristianRolfo From a practical standpoint, ctDNA liquid biopsy isn't a reliable way to examine the genetics of CNS disease or CNS-only progression. Sometimes using a ctDNA assay in the CSF can be informative though, especially in the setting of LMD #LCSM |
| Christian Rolfo @ChristianRolfo @DrSteveMartin @CharuAggarwalMD Unfortunately youβre completely right, outside US the price for get this technology itβs very expensive for patients and we need to make accesible worldwide π. Testing itβs a must not a luxury #lcsm @isliquidbiopsy in several countries they started to cover small panels |
| Dr. Amy C. Moore @acmoorephd @JFreemanDaily @lcsmchat Help, I can't keep up! #lcsm |
| Kristin Ito @KAdvocate_LCAM RT @JFreemanDaily: T4. How might liquid biopsy be used for early detection of cancer? #lcsm |
| Janet Freeman-Daily @JFreemanDaily #LCSM |
| Matthew Smeltzer @MattSmeltzer T4. Liquid biopsy and LDCT in series or in parallel? #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T4. How might liquid biopsy be used for early detection of cancer? #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| Lecia Sequist, MD, MPH @LeciaSequist T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @JFreemanDaily @CharuAggarwalMD @ChristianRolfo From a practical standpoint, ctDNA liquid biopsy isn't a reliable way to examine the genetics of CNS disease or CNS-only progression. Sometimes using a ctDNA assay in the CSF can be informative though, especially in the setting of LMD #LCSM |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: @DrSteveMartin @CharuAggarwalMD Unfortunately youβre completely right, outside US the price for get this technology itβs very expensive for patients and we need to make accesible worldwide π. Testing itβs a must not a luxury #lcsm @isliquidbiopsy in several countries they started to cover small panels |
| Danielle Pardue @Actorielle RT @JFreemanDaily: T4. How might liquid biopsy be used for early detection of cancer? #lcsm |
| Nirmal Raut @oncologician @ChristianRolfo @CharuAggarwalMD @aparna1024 @isliquidbiopsy #LCSM Arent we missing the oppurtunity here to create memory T cell by not using Neo adjuvant IO @FordePatrick |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T4: T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| #LCSM Chat @lcsmchat RT @MattSmeltzer: T4. Liquid biopsy and LDCT in series or in parallel? #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| Lisa Briggs @livinglife82 @JFreemanDaily T1: Are fusions more difficult to detect via #liquidbiopsy because they are more vulnerable/unstable and prone to damage with transportation etc? My understanding is that this can be a problem with tissue biopsies? #LCSM @lcsmchat |
| Upstage Lung Cancer @UpstageLungCanc RT @JFreemanDaily: T4. How might liquid biopsy be used for early detection of cancer? #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T4: T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM |
| Kristin Ito @KAdvocate_LCAM RT @ChristianRolfo: @DrSteveMartin @CharuAggarwalMD Unfortunately youβre completely right, outside US the price for get this technology itβs very expensive for patients and we need to make accesible worldwide π. Testing itβs a must not a luxury #lcsm @isliquidbiopsy in several countries they started to cover small panels |
| Lecia Sequist, MD, MPH @LeciaSequist T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2 |
| Lecia Sequist, MD, MPH @LeciaSequist T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc |
| #LCSM Chat @lcsmchat RT @livinglife82: @JFreemanDaily T1: @JFreemanDaily T1: Are fusions more difficult to detect via #liquidbiopsy because they are more vulnerable/unstable and prone to damage with transportation etc? My understanding is that this can be a problem with tissue biopsies? #LCSM @lcsmchat |
| Danielle Pardue @Actorielle RT @LeciaSequist: T4: T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| Janet Freeman-Daily @JFreemanDaily #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2 |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc |
 | b_hring_m @b_hring_m RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| kristen kimball @KimballKristen Someday may screening for LC be as common as colonoscopies and mammograms! #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM |
| Nirmal Raut @oncologician RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc |
| #LCSM Chat @lcsmchat RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @JFreemanDaily @CharuAggarwalMD @ChristianRolfo From a practical standpoint, ctDNA liquid biopsy isn't a reliable way to examine the genetics of CNS disease or CNS-only progression. Sometimes using a ctDNA assay in the CSF can be informative though, especially in the setting of LMD #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2 |
| #LCSM Chat @lcsmchat RT @KimballKristen: Someday may screening for LC be as common as colonoscopies and mammograms! #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM |
| Janet Freeman-Daily @JFreemanDaily @acmoorephd @lcsmchat I know the feeling ... #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM |
| kristen kimball @KimballKristen RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| Danielle Pardue @Actorielle RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc |
| Janet Freeman-Daily @JFreemanDaily RT @livinglife82: @JFreemanDaily T1: @JFreemanDaily T1: Are fusions more difficult to detect via #liquidbiopsy because they are more vulnerable/unstable and prone to damage with transportation etc? My understanding is that this can be a problem with tissue biopsies? #LCSM @lcsmchat |
| Danielle Pardue @Actorielle RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2 |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z |
| Danielle Pardue @Actorielle RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM |
| Danielle Pardue @Actorielle RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM |
 | Ilene Kaminsky @ilenealizah Iβve had one, they do work in some cases. Thankfully mine. |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z |
| Dave Bjork @bjork5 This! π #lcsm |
| Jill Feldman @jillfeldman4 T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM |
| Janet Freeman-Daily @JFreemanDaily #LCSM |
| Erika Hlavacek @ErikaHlavacek @ChristianRolfo @DrSteveMartin @CharuAggarwalMD @isliquidbiopsy We forgot how good we have it, and take our medical coverage for granted. I'm humbled hearing what happens elsewhere and very sad for my fellow pts. #lcsm |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw |
| Janet Freeman-Daily @JFreemanDaily #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z |
| #LCSM Chat @lcsmchat RT @ErikaHlavacek: @ChristianRolfo @DrSteveMartin @CharuAggarwalMD @isliquidbiopsy We forgot how good we have it, and take our medical coverage for granted. I'm humbled hearing what happens elsewhere and very sad for my fellow pts. #lcsm |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw |
 | Guardant Health @GuardantHealth RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj |
| Janet Freeman-Daily @JFreemanDaily Please remember to include #LCSM in all your tweets during #LCSM Chat so all the chat participants will see them. |
| Gia Sonata @RedGia T4. #lcsm please see below. I forgot the tags ;) |
| kristen kimball @KimballKristen RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #LCSM |
| Luis E Raez @LuisERaez1 This is one of the potential applications of liquid biopsy that needs to be explore! #LCSM @isliquidbiopsy |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Please remember to include #LCSM in all your tweets during #LCSM Chat so all the chat participants will see them. |
 | Venky (Venkatraman Radhakrishnan) @venkymd RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T4: T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM |
| Nirmal Raut @oncologician @LeciaSequist Wondering if this will more applicable in Asian countries where the incidence of EGFR is ~40% #LCSM |
| Christian Rolfo @ChristianRolfo @CharuAggarwalMD #lcsm including cancer interception, so to identify all the process are involved in cancer start. https://t.co/JZzlotz2Pu @MJOSESERRANO19 @CD_AACR @isliquidbiopsy https://t.co/zxLU9LzLgf |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
 | Monkeyπππ @Monkey26697239 RT @MDAndersonNews: An MD Anderson study has defined a previously unknown fourth type of small-cell lung cancer and offers new therapeutic strategies: https://t.co/K2Ur27eZxj @LaurenByersMD #LCSM #EndCancer |
| #LCSM Chat @lcsmchat RT @RedGia: T4. #lcsm please see below. I forgot the tags ;) |
| Janet Freeman-Daily @JFreemanDaily RT @MattSmeltzer: T4. Liquid biopsy and LDCT in series or in parallel? #LCSM |
| #LCSM Chat @lcsmchat RT @LuisERaez1: This is one of the potential applications of liquid biopsy that needs to be explore! #LCSM @isliquidbiopsy |
| #LCSM Chat @lcsmchat RT @oncologician: @LeciaSequist Wondering if this will more applicable in Asian countries where the incidence of EGFR is ~40% #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist I hope that this assay (called Lung-CLiP) could be used in the future to help differentiate benign from cancerous lung nodules #LCSM @max_diehn |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: @CharuAggarwalMD #lcsm including cancer interception, so to identify all the process are involved in cancer start. https://t.co/JZzlotz2Pu @MJOSESERRANO19 @CD_AACR @isliquidbiopsy https://t.co/zxLU9LzLgf |
| Nirmal Raut @oncologician RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2 |
| Upstage Lung Cancer @UpstageLungCanc RT @JFreemanDaily: #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: I hope that this assay (called Lung-CLiP) could be used in the future to help differentiate benign from cancerous lung nodules #LCSM @max_diehn |
| Erika Hlavacek @ErikaHlavacek You were in my STARS Program final presentation slides on Early Detection for your collaboration with SU2C and Lungevity. Exciting work, thank you! #lcsm |
| Nirmal Raut @oncologician RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @RedGia I think that is a very difficult question to answer with a liquid bx. #LCSM |
| #LCSM Chat @lcsmchat RT @ErikaHlavacek: You were in my STARS Program final presentation slides on Early Detection for your collaboration with SU2C and Lungevity. Exciting work, thank you! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @oncologician @ChristianRolfo @CharuAggarwalMD @aparna1024 @isliquidbiopsy @FordePatrick This chat is focused on #liquidbiopsy rather than treatment options. Hopefully one of the guests will have an opportunity to respond after the chat. Thanks for participating! #LCSM |
| Jill Feldman @jillfeldman4 RT @LeciaSequist: I hope that this assay (called Lung-CLiP) could be used in the future to help differentiate benign from cancerous lung nodules #LCSM @max_diehn |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc |
| Danielle Pardue @Actorielle RT @ChristianRolfo: @CharuAggarwalMD #lcsm including cancer interception, so to identify all the process are involved in cancer start. https://t.co/JZzlotz2Pu @MJOSESERRANO19 @CD_AACR @isliquidbiopsy https://t.co/zxLU9LzLgf |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2 |
| Erika Hlavacek @ErikaHlavacek Future of lung cancer. How far we have come. #lcsm |
| Danielle Pardue @Actorielle RT @JFreemanDaily: #LCSM |
| Danielle Pardue @Actorielle RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM |
| Dr. Amy C. Moore @acmoorephd RT @JFreemanDaily: #LCSM |
| Matthew Smeltzer @MattSmeltzer RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw |
| Danielle Pardue @Actorielle RT @jillfeldman4: T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM |
| Luis E Raez @LuisERaez1 T1. Agree, however there is a lot to explore with cfRNA and exosomal RNA that can provide valuable information too, more research is needed #LCSM @isliquidbiopsy |
| Janet Freeman-Daily @JFreemanDaily RT @KimballKristen: Someday may screening for LC be as common as colonoscopies and mammograms! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z |
| #LCSM Chat @lcsmchat RT @LuisERaez1: T1. Agree, however there is a lot to explore with cfRNA and exosomal RNA that can provide valuable information too, more research is needed #LCSM @isliquidbiopsy |
| Lisa Briggs @livinglife82 Sounds optimistic, however given the number of variables determining the outcome, perhaps thereβs a role for #liquidbiopsies to confirm uncertainties detected through scans via #lungcancer #screening programs until sensitivity & precision improves? #lcsm @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @ErikaHlavacek: @ChristianRolfo @DrSteveMartin @CharuAggarwalMD @isliquidbiopsy We forgot how good we have it, and take our medical coverage for granted. I'm humbled hearing what happens elsewhere and very sad for my fellow pts. #lcsm |
| Gia Sonata @RedGia @CharuAggarwalMD Thanks. Worth a shot! #lcsm |
| #LCSM Chat @lcsmchat RT @livinglife82: Sounds optimistic, however given the number of variables determining the outcome, perhaps thereβs a role for #liquidbiopsies to confirm uncertainties detected through scans via #lungcancer #screening programs until sensitivity & precision improves? #lcsm @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw |
| Jill Feldman @jillfeldman4 RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl |
| Janet Freeman-Daily @JFreemanDaily RT @RedGia: T4. #lcsm please see below. I forgot the tags ;) |
| Erika Hlavacek @ErikaHlavacek RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc |
| Lecia Sequist, MD, MPH @LeciaSequist @livinglife82 @lcsmchat I agree this is a really good setting for liquid biopsies to start π #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LuisERaez1: This is one of the potential applications of liquid biopsy that needs to be explore! #LCSM @isliquidbiopsy |
| Jill Feldman @jillfeldman4 RT @LuisERaez1: This is one of the potential applications of liquid biopsy that needs to be explore! #LCSM @isliquidbiopsy |
 | Hari B. Keshava @hari_keshava RT @jillfeldman4: T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM |
| Dr. Amy C. Moore @acmoorephd T4. I would say @GO2Foundation is very motivated to leverage our Centers of Excellence, including sites focused on best practices for LDCT screening, and couple that with ALCMI's capabilities in remote studies and liquid Bx to push the envelope on early #cancer detection. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @RedGia Please correct me if I'm wrong, but at present, we can't tell if cfDNA comes from a living cell or a cell that died and is breaking down, correct? #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4 |
| Janet Freeman-Daily @JFreemanDaily RT @oncologician: @LeciaSequist Wondering if this will more applicable in Asian countries where the incidence of EGFR is ~40% #LCSM |
| #LCSM Chat @lcsmchat RT @acmoorephd: T4. I would say @GO2Foundation is very motivated to leverage our Centers of Excellence, including sites focused on best practices for LDCT screening, and couple that with ALCMI's capabilities in remote studies and liquid Bx to push the envelope on early #cancer detection. #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @RedGia Please correct me if I'm wrong, but at present, we can't tell if cfDNA comes from a living cell or a cell that died and is breaking down, correct? #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: @CharuAggarwalMD #lcsm including cancer interception, so to identify all the process are involved in cancer start. https://t.co/JZzlotz2Pu @MJOSESERRANO19 @CD_AACR @isliquidbiopsy https://t.co/zxLU9LzLgf |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4 |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: I hope that this assay (called Lung-CLiP) could be used in the future to help differentiate benign from cancerous lung nodules #LCSM @max_diehn |
| Janet Freeman-Daily @JFreemanDaily RT @ErikaHlavacek: You were in my STARS Program final presentation slides on Early Detection for your collaboration with SU2C and Lungevity. Exciting work, thank you! #lcsm |
| Erika Hlavacek @ErikaHlavacek Dream: Breast mammogram & lung cancer screening given together! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @RedGia I think that is a very difficult question to answer with a liquid bx. #LCSM |
| Nirmal Raut @oncologician RT @LeciaSequist: @JFreemanDaily @CharuAggarwalMD @ChristianRolfo From a practical standpoint, ctDNA liquid biopsy isn't a reliable way to examine the genetics of CNS disease or CNS-only progression. Sometimes using a ctDNA assay in the CSF can be informative though, especially in the setting of LMD #LCSM |
| Upstage Lung Cancer @UpstageLungCanc Always a pleasure to learn from the work our friends at @GO2Foundation are doing! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @ErikaHlavacek: Future of lung cancer. How far we have come. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @LuisERaez1: T1. Agree, however there is a lot to explore with cfRNA and exosomal RNA that can provide valuable information too, more research is needed #LCSM @isliquidbiopsy |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell RT @CharuAggarwalMD: We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4 |
| Lisa Briggs @livinglife82 Wouldnβt this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat |
| Gia Sonata @RedGia RT @ErikaHlavacek: Dream: Dream: Breast mammogram & lung cancer screening given together! #lcsm |
| Danielle Pardue @Actorielle RT @livinglife82: Wouldnβt this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @livinglife82: Sounds optimistic, however given the number of variables determining the outcome, perhaps thereβs a role for #liquidbiopsies to confirm uncertainties detected through scans via #lungcancer #screening programs until sensitivity & precision improves? #lcsm @lcsmchat |
| Danielle Pardue @Actorielle RT @ErikaHlavacek: Dream: Dream: Breast mammogram & lung cancer screening given together! #lcsm |
| Lecia Sequist, MD, MPH @LeciaSequist @JFreemanDaily @RedGia Not by looking at the DNA. There is the potential for some liquid biopsies to tell us more about function and current activity in the body, but these are far from the clinic. I'm thinking of RNA, proteomics, even exosomes. #LCSM |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4 |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @livinglife82 @lcsmchat I agree this is a really good setting for liquid biopsies to start π #LCSM |
| Christian Rolfo @ChristianRolfo #lcsm @LeciaSequist @CharuAggarwalMD @JFreemanDaily an important aspect is also the interpretation of LB results. Molecular Tumor Boards are a great tool to avoid problems in results interpretation. Multidisciplinary knowledge is needed . |
| #LCSM Chat @lcsmchat RT @ErikaHlavacek: Dream: Dream: Breast mammogram & lung cancer screening given together! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: T4. I would say @GO2Foundation is very motivated to leverage our Centers of Excellence, including sites focused on best practices for LDCT screening, and couple that with ALCMI's capabilities in remote studies and liquid Bx to push the envelope on early #cancer detection. #lcsm |
| #LCSM Chat @lcsmchat RT @livinglife82: Wouldnβt this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4 |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @JFreemanDaily @RedGia Not by looking at the DNA. There is the potential for some liquid biopsies to tell us more about function and current activity in the body, but these are far from the clinic. I'm thinking of RNA, proteomics, even exosomes. #LCSM |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: #lcsm @LeciaSequist @CharuAggarwalMD @JFreemanDaily an important aspect is also the interpretation of LB results. Molecular Tumor Boards are a great tool to avoid problems in results interpretation. Multidisciplinary knowledge is needed . |
| Janet Freeman-Daily @JFreemanDaily RT @ErikaHlavacek: Dream: Dream: Breast mammogram & lung cancer screening given together! #lcsm |
| Gia Sonata @RedGia @livinglife82 @lcsmchat You had me at "less invasive" #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @UpstageLungCanc: Always a pleasure to learn from the work our friends at @GO2Foundation are doing! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @livinglife82: Wouldnβt this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @JFreemanDaily @RedGia Not by looking at the DNA. There is the potential for some liquid biopsies to tell us more about function and current activity in the body, but these are far from the clinic. I'm thinking of RNA, proteomics, even exosomes. #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: #lcsm @LeciaSequist @CharuAggarwalMD @JFreemanDaily an important aspect is also the interpretation of LB results. Molecular Tumor Boards are a great tool to avoid problems in results interpretation. Multidisciplinary knowledge is needed . |
| Janet Freeman-Daily @JFreemanDaily RT @RedGia: @livinglife82 @lcsmchat You had me at "less invasive" #lcsm |
| Nirmal Raut @oncologician RT @ErikaHlavacek: Future of lung cancer. How far we have come. #lcsm |
| Christian Rolfo @ChristianRolfo RT @CharuAggarwalMD: Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM |
| Janet Freeman-Daily @JFreemanDaily Weβre in our final minutes - closing thoughts? #lcsm |
| Gia Sonata @RedGia @LeciaSequist @JFreemanDaily Thank you both for the add'l info. #lcsm |
| #LCSM Chat @lcsmchat RT @RedGia: @livinglife82 @lcsmchat You had me at "less invasive" #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM |
| #LCSM Chat @lcsmchat RT @LeciaSequist: Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Weβre in our final minutes - closing thoughts? #lcsm |
| Gia Sonata @RedGia RT @LeciaSequist: Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM |
 | Live.Breathe.Survive @LBSShow RT @LUNGevity: Drug Approval Alert: Drug Approval Alert: The FDA has expanded the indication for lorlatinib to include the front-line treatment of patients with ALK+ metastatic #NSCLC: https://t.co/V6Xf9KabGG #LCSM |
| Christian Rolfo @ChristianRolfo We hope we will see soon published! #lcsm great team of experts from @IASLC @drgandara |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: We hope we will see soon published! #lcsm great team of experts from @IASLC @drgandara |
 | Anne Ireland, DNP, RN, AOCN, CENP @ONSAIreland Proud to be part of open notes @cityofhope |
| Upstage Lung Cancer @UpstageLungCanc RT @LeciaSequist: Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @CharuAggarwalMD: Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @JFreemanDaily Thank you for the invitation to hang with the awesome #LCSM crew! |
| Upstage Lung Cancer @UpstageLungCanc RT @livinglife82: Wouldnβt this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat |
| Dave Bjork @bjork5 Thank you @LeciaSequist and @CharuAggarwalMD for your commitment to lung cancer patients & reseach #LCSM #liquidbiopsy #PrecisionMedicine |
| #LCSM Chat @lcsmchat Many thanks to our rockstars @JFreemanDaily @LeciaSequist @CharuAggarwalMD for their invaluable work on this chat. #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist @CharuAggarwalMD @JFreemanDaily This chat was so much fun - thank you #LCSM |
| Nirmal Raut @oncologician @livinglife82 @lcsmchat And Utopian if affordable too #lcsm |
| Dr. Amy C. Moore @acmoorephd @JFreemanDaily @lcsmchat Only that I am so thankful there are so many smart people working on this! WOW. #lcsm |
| Kristin Ito @KAdvocate_LCAM Definitely going to have to take time to go back through all of the resources shared tonight! I appreciate you all! #LCSM |
| Upstage Lung Cancer @UpstageLungCanc Thank you so much to the fantastic moderators and distinguished guests and educators! This chat is always phenomenal. #lcsm |
| Janet Freeman-Daily @JFreemanDaily A HUGE thank you to our #LCSM Chat special guests tonight @CharuAggarwalMD and @LeciaSequist for a flood of informative, easy to understand tweets! I will definitely be creating a @wakelet summary of this chat! I learned SO much! |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: A HUGE thank you to our #LCSM Chat special guests tonight @CharuAggarwalMD and @LeciaSequist for a flood of informative, easy to understand tweets! I will definitely be creating a @wakelet summary of this chat! I learned SO much! |
| Danielle Pardue @Actorielle @KAdvocate_LCAM Saaaaaame! πππ #lcsm |
| Denise Cutlip @dennycee Thank you for a highly informative chat #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM |
| Danielle Pardue @Actorielle RT @lcsmchat: Many thanks to our rockstars @JFreemanDaily @LeciaSequist @CharuAggarwalMD for their invaluable work on this chat. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM |
| Nathan A. Pennell MD, PhD, FASCO @n8pennell My closing thoughts are that this has been one of the best #lcsm chats ever, such a great job by @LeciaSequist and @CharuAggarwalMD (and @JFreemanDaily)! |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: We hope we will see soon published! #lcsm great team of experts from @IASLC @drgandara |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @JFreemanDaily Thank you for the invitation to hang with the awesome #LCSM crew! |
| Janet Freeman-Daily @JFreemanDaily RT @bjork5: Thank you @LeciaSequist and @CharuAggarwalMD for your commitment to lung cancer patients & reseach #LCSM #liquidbiopsy #PrecisionMedicine |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @JFreemanDaily @LeciaSequist @wakelet It was awesome! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @lcsmchat: Many thanks to our rockstars @JFreemanDaily @LeciaSequist @CharuAggarwalMD for their invaluable work on this chat. #LCSM |
| Danielle Pardue @Actorielle Thank you #lcsm team! You all are the BEST! What a mind-blowing chat! π |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: @CharuAggarwalMD @JFreemanDaily This chat was so much fun - thank you #LCSM |
| Danielle Pardue @Actorielle RT @JFreemanDaily: A HUGE thank you to our #LCSM Chat special guests tonight @CharuAggarwalMD and @LeciaSequist for a flood of informative, easy to understand tweets! I will definitely be creating a @wakelet summary of this chat! I learned SO much! |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: @JFreemanDaily @lcsmchat Only that I am so thankful there are so many smart people working on this! WOW. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @KAdvocate_LCAM: Definitely going to have to take time to go back through all of the resources shared tonight! I appreciate you all! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @UpstageLungCanc: Thank you so much to the fantastic moderators and distinguished guests and educators! This chat is always phenomenal. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @Actorielle: @KAdvocate_LCAM Saaaaaame! πππ #lcsm |
| Matthew Smeltzer @MattSmeltzer Great discussion, so much info! Thanks @LeciaSequist @CharuAggarwalMD @JFreemanDaily @IASLC #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @dennycee: Thank you for a highly informative chat #lcsm |
| Christian Rolfo @ChristianRolfo @JFreemanDaily 1-Understanding benefits and limitations of LB is crucial for correct application. 2- we need to make accessible to all the patients.3-education for the medical community for order the correct test, to interpret results 4-ctDNA is a robust tool for testing, not experimental!#lcsm |
| Lisa Briggs @livinglife82 T4 - Ha ha. I literally just made this suggestion. At least until we can improve the sensitivity of the test to detect low levels of ctDNA...then who knows #liquidbiopsies may well be our future π€·π»ββοΈ #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @n8pennell: My closing thoughts are that this has been one of the best #lcsm chats ever, such a great job by @LeciaSequist and @CharuAggarwalMD (and @JFreemanDaily)! |
 | Nicole Karapanagiotis, Ph.D. @ProfessorNK Joining late from Wilmington, DE. Will read through everything now. Just logging my attendance. Thanks, everyone! #LCSM |
| Peggy Dennis @peggyddennis Many thanks. I look forward to reading through the transcript to see what I missed! #lcsm |
| kristen kimball @KimballKristen Thank you so much, @LeciaSequist @CharuAggarwalMD! and @JFreemanDaily and @LungCancerFaces - I so appreciate keeping up and staying in touch with #lungcancer community via these chats. #LCSM |
| Janet Freeman-Daily @JFreemanDaily #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist @wakelet It was awesome! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @Actorielle: Thank you #lcsm team! You all are the BEST! What a mind-blowing chat! π |
| Janet Freeman-Daily @JFreemanDaily RT @MattSmeltzer: Great discussion, so much info! Thanks @LeciaSequist @CharuAggarwalMD @JFreemanDaily @IASLC #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: @JFreemanDaily 1-Understanding benefits and limitations of LB is crucial for correct application. 2- we need to make accessible to all the patients.3-education for the medical community for order the correct test, to interpret results 4-ctDNA is a robust tool for testing, not experimental!#lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @livinglife82: T4 - Ha ha. I literally just made this suggestion. At least until we can improve the sensitivity of the test to detect low levels of ctDNA...then who knows #liquidbiopsies may well be our future π€·π»ββοΈ #LCSM |
| Lecia Sequist, MD, MPH @LeciaSequist This π #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @ProfessorNK: Joining late from Wilmington, DE. Will read through everything now. Just logging my attendance. Thanks, everyone! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @peggyddennis: Many thanks. I look forward to reading through the transcript to see what I missed! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @KimballKristen: Thank you so much, @LeciaSequist @CharuAggarwalMD! and @JFreemanDaily and @LungCancerFaces - I so appreciate keeping up and staying in touch with #lungcancer community via these chats. #LCSM |
| Triage Cancer @TriageCancer Such an honor to be in this conversation tonight! Thank you #lcsm team! |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: This π #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @LeciaSequist: This π #LCSM |
| Danielle Pardue @Actorielle RT @n8pennell: My closing thoughts are that this has been one of the best #lcsm chats ever, such a great job by @LeciaSequist and @CharuAggarwalMD (and @JFreemanDaily)! |
| Lisa Briggs @livinglife82 Agree! Thank you @JFreemanDaily @LeciaSequist and @CharuAggarwalMD πππ #LCSM @lcsmchat #liquidbiopsy #lungcancer #ourfuture |
| Christian Rolfo @ChristianRolfo Great chat! And great team! Thanks @LeciaSequist @CharuAggarwalMD and @JFreemanDaily for lead this interesting debate! @lcsmchat #lcsm @isliquidbiopsy https://t.co/iJEMjj4Ydy |
| Upstage Lung Cancer @UpstageLungCanc RT @livinglife82: Agree! Thank you @JFreemanDaily @LeciaSequist and @CharuAggarwalMD πππ #LCSM @lcsmchat #liquidbiopsy #lungcancer #ourfuture |
| Janet Freeman-Daily @JFreemanDaily RT @livinglife82: Agree! Thank you @JFreemanDaily @LeciaSequist and @CharuAggarwalMD πππ #LCSM @lcsmchat #liquidbiopsy #lungcancer #ourfuture |
| Dr. Amy C. Moore @acmoorephd This was an incredibly informative #LCSM Chat with two powerhouses, @CharuAggarwalMD and @LeciaSequist. I am the student, they are the teachers. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @acmoorephd: This was an incredibly informative #LCSM Chat with two powerhouses, @CharuAggarwalMD and @LeciaSequist. I am the student, they are the teachers. #lcsm |
| #LCSM Chat @lcsmchat RT @n8pennell: My closing thoughts are that this has been one of the best #lcsm chats ever, such a great job by @LeciaSequist and @CharuAggarwalMD (and @JFreemanDaily)! |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: @JFreemanDaily 1-Understanding benefits and limitations of LB is crucial for correct application. 2- we need to make accessible to all the patients.3-education for the medical community for order the correct test, to interpret results 4-ctDNA is a robust tool for testing, not experimental!#lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @ChristianRolfo: Great chat! And great team! Thanks @LeciaSequist @CharuAggarwalMD and @JFreemanDaily for lead this interesting debate! @lcsmchat #lcsm @isliquidbiopsy https://t.co/iJEMjj4Ydy |
| #LCSM Chat @lcsmchat RT @livinglife82: T4 - Ha ha. I literally just made this suggestion. At least until we can improve the sensitivity of the test to detect low levels of ctDNA...then who knows #liquidbiopsies may well be our future π€·π»ββοΈ #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @TriageCancer: Such an honor to be in this conversation tonight! Thank you #lcsm team! |
| Dr. Amy C. Moore @acmoorephd Hope on the horizon for liquid bx in #lungcancer #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @ChristianRolfo @LeciaSequist @JFreemanDaily @lcsmchat @isliquidbiopsy Thank YOU for the incredible wealth of information! #LCSM |
 | Dr Amol Akhade @SuyogCancer RT @LeciaSequist: T1: T1: An advantage for liq bx - they are less invasive/just a blood draw! However, you may not find material and a negative test does not prove "absence". As @dave6408 once said, not catching a fish doesn't mean the lake is empty. #LCSM https://t.co/skiLuQ96bP |
| Nirmal Raut @oncologician RT @ChristianRolfo: @JFreemanDaily 1-Understanding benefits and limitations of LB is crucial for correct application. 2- we need to make accessible to all the patients.3-education for the medical community for order the correct test, to interpret results 4-ctDNA is a robust tool for testing, not experimental!#lcsm |
| #LCSM Chat @lcsmchat Special shout-out to @ChristianRolfo for his stellar contributions to tonightβs #lcsm chat. |
 | Nicole Kuderer, MD, MS, FASCO ππΊπΈπͺπΊπΊπ¦π @NicoleKuderer RT @CharuAggarwalMD: T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195 |
#LCSM content from Twitter.